Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Common Equity (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Common Equity for 5 consecutive years, with $70.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 40.07% to $70.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.1 million through Dec 2025, down 40.07% year-over-year, with the annual reading at $70.1 million for FY2025, 40.07% down from the prior year.
  • Common Equity hit $70.1 million in Q4 2025 for Kezar Life Sciences, down from $83.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $297.4 million in Q2 2022 to a low of $70.1 million in Q4 2025.
  • Historically, Common Equity has averaged $173.8 million across 5 years, with a median of $159.9 million in 2024.
  • Biggest five-year swings in Common Equity: surged 137.02% in 2022 and later crashed 40.07% in 2025.
  • Year by year, Common Equity stood at $196.9 million in 2021, then surged by 37.08% to $269.9 million in 2022, then tumbled by 30.5% to $187.6 million in 2023, then plummeted by 37.67% to $116.9 million in 2024, then plummeted by 40.07% to $70.1 million in 2025.
  • Business Quant data shows Common Equity for KZR at $70.1 million in Q4 2025, $83.0 million in Q3 2025, and $91.8 million in Q2 2025.